Phase 2a Randomized, Single-Blind, Placebo-Controlled, 12-week Escalating Dose Study to Assess the Safety, Tolerability and Clinical Activity of 3 Concentrations of Locally Applied MBN-101 to Infected Bone Sites

Trial Profile

Phase 2a Randomized, Single-Blind, Placebo-Controlled, 12-week Escalating Dose Study to Assess the Safety, Tolerability and Clinical Activity of 3 Concentrations of Locally Applied MBN-101 to Infected Bone Sites

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs MBN 101 (Primary)
  • Indications Bacterial infections
  • Focus Adverse reactions
  • Sponsors Microbion Corporation
  • Most Recent Events

    • 08 Nov 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2018.
    • 08 Nov 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2018.
    • 14 Feb 2017 Planned number of patients changed from 36 to 24.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top